PARP1 and Parkinson disease: Given that PARP-1 inhibition with selective inhibitors lessens neurodegeneration and demyelination in several animal disease models (e.g., PD, AD, and MS) and improves symptoms, via a reduction in the expression of inflammatory cytokines, we investigated the effects of Olaparib, a PARP inhibitor, on our sulfatide-treated slice culture model.